

COVID-19 Vaccine Efficacy on Omicron Variant

Attapon Cheepsattayakorn^{1,2*}, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand

²10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

***Corresponding Author:** Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

B.1.1.529 or Omicron variant, a variant of concern, designated by the World Health Organization (WHO) on November 26, 2021, on the suggestion of the WHO's Technical Advisory Group on Virus Evolution (TAG-VE) [1]. Whether Omicron variant is more transmissible or causes more severe COVID-19 is not yet clear compared to other SARS-CoV-2 (COVID-19) variants, including Delta variant [1]. Several epidemiological studies are ongoing in South Africa, first country of Omicron variant identification with rising of number of SARS-CoV-2 (COVID-19)-positive persons [1]. Currently, no information on different Omicron-related symptoms is available, compared to other COVID-19 variants [1]. Increased risk of Omicron-variant reinfection could easily occur in individuals with previous COVID-19 infection [1]. Reverse-transcriptase-polymerase-chain reaction (RT-PCR) continuously is the method of Omicron variant detection [1]. A recent study in England demonstrated that the vaccine efficacy (VE) after 15 weeks of two doses of BNT162b2 (Pfizer) vaccine was around 88.0 %, whereas there was no effect against Omicron variant after two doses of ChAdOx1 (AstraZeneca) vaccine [2]. Effectiveness of current treatments currently underway [1].

Bibliography

1. World Health Organization. "Update on Omicron" (2021).
2. Andrews N., *et al.* "Posted on December 14, 2021. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern". *medRxiv* (2021).

Received: December 22, 2021

Published: January 01, 2022

© All rights are reserved by **Attapon Cheepsattayakorn, et al.**

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: www.actascientific.com/

Submit Article: www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667